We have a great program this year. Anshul Kundaje (anshulkundaje@bluesky) will be giving the keynote address, 8 exciting talks by junior trainees, and a panel on defining career paths. Panelists include Wei-Lun Alterovitz from U.S. FDA , Carlos L. Araya, Monkol Lek, @LuluP78 and Xin Wang from 23andMe

We are looking forward to the Gordon Research Seminar on Human Genetic Variation and Disease; if you’re excited about the impact of large-scale functional genomics, computational biophysics, and machine learning come meet our CEO Carlos L. Araya at the Career Development Panel.

Enter an era of high-throughout, quantitative assays of biomolecular function. x.com/wjgreenleaf/st…

Enjoyed visit from @InaldeBS & IAE Business School to explore #Innovation-Special thanks to Carlos Jungla Inc., a #JLABSBay resident company. Shared his experience & work in AI-driven biotechnology to improve #genetic testing. Bonus-he delivered in our guests native language:) Christopher Lalli

We are delighted to be working with HPE to bring state-of-the-art #biophysics and memory-driven computing into quantitative, mechanistic support for #precisionmedicine! With 250x speed-ups (48TB RAM) patients can receive the most advanced support on-demand. #ai #beyondsequencing

HPE and biotech startup Jungla Inc. announce challenge to enable real-time, personalized medical care for patients under Tech Impact 2030. Read more: hpe.to/6004EESEm

ML combined with domain knowledge can push way beyond what ML can do alone. Jungla Inc. combines ML with several other methods, including insights from biophysics, cellular engineering, and distributed systems, to make considerably more accurate predictions of genomic variants.

Learn how Jungla Inc. has developed a cloud-based Molecular Evidence Platform (MEP) to help clinicians and patients understand the results of genetic and genomic tests... buff.ly/2ShTbcR . #IndieBio @SOSVvc

Time is often the most valuable resource in the medical community. I'm excited to share that, together, HPE and Jungla Inc. are aiming to transform the world of medicine as we know it by reducing precious research time from years to weeks. news.hpe.com/hewlett-packar… #HPEDiscover

10+ new tests *each day* in US, yet vast majority of reported variants are still not understood: ~95 unknown per known disease-causing variant in most modern tests! We need tech for *computational* clinical genetics & genomics interpretation...and Jungla Inc. can help!

Variants of Unknown Significance (VUS) remain a major challenge for interpreting genomic data. Jungla Inc. is working to advance our ability to make sense of our DNA.

Jungla embraces transparency, utilizing blockchain to make the Molecular Evidence Platform auditable - learn more from a recent interview between cofounder @acolavin and Tierion CEO Wayne Vaughan. tnt.tl/2RO7o17

In an interview with GenomeWeb, Jungla CEO Carlos L. Araya shares why three scientists from Stanford University came together to help make genomes more meaningful. Read more about the mission that Carlos L. Araya, @acolavin, and Jason Reuter have undertaken: bit.ly/2Fk4wG7

Enhancing today’s largely observational #clinical #genetics infrastructure with a model-driven framework can bring #patients tests that are #quantitative, #auditable, #comprehensive, and increasingly #mechanistic. BioTechniques interviews CEO Carlos L. Araya: bit.ly/jungla-biotech…

If you’re in Seattle and excited about building a scalable, mechanistic platform for clinical genetics and genomics, come grab a beer. It’s on us: Big Time Brewery from 5:30-7:30pm (Today)!

We're excited to be working to enhance molecular evidence for our field! #ACMGMtg17

We are proud to be a part of the growing healthcare innovation efforts that seek to make genomic information more actionable and reliable for all. x.com/JorgeCondeBio/…